CCN2 and pulmonary fibrosis: For instance, Pamrevlumab (also known as FG‐3019), a humanized anti‐CTGF antibody, has undergone extensive clinical trials for conditions such as muscular dystrophy, liver fibrosis, idiopathic pulmonary fibrosis and pancreatic cancer.67, 68